Compare TCX & PEPG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TCX | PEPG |
|---|---|---|
| Founded | 1992 | 2018 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 167.0M | 179.4M |
| IPO Year | 2005 | 2022 |
| Metric | TCX | PEPG |
|---|---|---|
| Price | $11.89 | $2.51 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $10.19 |
| AVG Volume (30 Days) | 67.4K | ★ 936.2K |
| Earning Date | 11-05-2026 | 11-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 25.61 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $362,275,000.00 | N/A |
| Revenue This Year | $26.83 | N/A |
| Revenue Next Year | $10.04 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 6.76 | N/A |
| 52 Week Low | $8.45 | $1.31 |
| 52 Week High | $25.17 | $7.80 |
| Indicator | TCX | PEPG |
|---|---|---|
| Relative Strength Index (RSI) | 65.27 | 45.94 |
| Support Level | $8.56 | $2.24 |
| Resistance Level | $15.69 | $2.62 |
| Average True Range (ATR) | 0.89 | 0.23 |
| MACD | 0.29 | 0.03 |
| Stochastic Oscillator | 91.67 | 32.20 |
Tucows Inc is a corporate parent, allocating capital and providing efficient shared services to its three businesses. The Company offers Mobile Service Enabler (MSE) solutions, as well as professional services to other retail mobile providers. The Company is also a distributor of Internet services, including domain name registration, digital certificates, and email. It provides these services through an Internet-based distribution network of Internet Service Providers, web hosting companies, and other providers of Internet services to end-users. It operates in three segments: Ting, Wavelo, and Tucows Domains. It generates the majority of its revenue from Tucows Domains. The company generates key revenue from Canada and USA.
PepGen Inc is a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapeutics to transform the treatment of severe neuromuscular and neurologic diseases. The company has developed its Enhanced Delivery Oligonucleotide platform to improve the uptake and activity of conjugated oligonucleotide therapeutics. Its EDO peptides are engineered to optimize tissue penetration, cellular uptake, and nuclear delivery, and in preclinical studies, it is observed that their ability to transport oligonucleotides into a broad range of target tissues, including smooth, skeletal, and cardiac muscle, and the central nervous system. Its pipeline products are: PGN-EDO51, PGN-EDODM1, and others.